Improving early phase oncology clinical trial design: An opportunity for statisticians
Authors: Phillips, A. and Mondal, S.
Journal: Pharmaceutical Statistics
Volume: 22
Issue: 3
Pages: 577-580
eISSN: 1539-1612
ISSN: 1539-1604
DOI: 10.1002/pst.2287
Abstract:This short communication supports that rule-based study designs such as the ‘3 + 3’ study design are still being used in early phase oncology development programs despite their inferior performance to model-based and model-assisted designs. Statisticians have an opportunity to shape and improve early phase oncology drug development programs by introducing newer, more efficient study designs that estimate the Optimal Biological dose to their oncology trialist colleges.
Source: Scopus
Improving early phase oncology clinical trial design: An opportunity for statisticians.
Authors: Phillips, A. and Mondal, S.
Journal: Pharm Stat
Volume: 22
Issue: 3
Pages: 577-580
eISSN: 1539-1612
DOI: 10.1002/pst.2287
Abstract:This short communication supports that rule-based study designs such as the '3 + 3' study design are still being used in early phase oncology development programs despite their inferior performance to model-based and model-assisted designs. Statisticians have an opportunity to shape and improve early phase oncology drug development programs by introducing newer, more efficient study designs that estimate the Optimal Biological dose to their oncology trialist colleges.
Source: PubMed
Improving early phase oncology clinical trial design: An opportunity for statisticians
Authors: Phillips, A. and Mondal, S.
Journal: PHARMACEUTICAL STATISTICS
Volume: 22
Issue: 3
Pages: 577-580
eISSN: 1539-1612
ISSN: 1539-1604
DOI: 10.1002/pst.2287
Source: Web of Science (Lite)
Improving early phase oncology clinical trial design: An opportunity for statisticians.
Authors: Phillips, A. and Mondal, S.
Journal: Pharmaceutical statistics
Volume: 22
Issue: 3
Pages: 577-580
eISSN: 1539-1612
ISSN: 1539-1604
DOI: 10.1002/pst.2287
Abstract:This short communication supports that rule-based study designs such as the '3 + 3' study design are still being used in early phase oncology development programs despite their inferior performance to model-based and model-assisted designs. Statisticians have an opportunity to shape and improve early phase oncology drug development programs by introducing newer, more efficient study designs that estimate the Optimal Biological dose to their oncology trialist colleges.
Source: Europe PubMed Central